Related Experiment Videos
Insights
Phototherapy for neonatal jaundice can cause riboflavin deficiency in newborns due to light sensitivity. Careful supplementation is needed to avoid adverse effects in infants undergoing this treatment.
Area of Science:
- Biochemistry
- Neonatal Medicine
- Photobiology
Background:
- Riboflavin (vitamin B2) and its nucleotides are crucial flavins highly sensitive to light.
- Riboflavin's presence in body fluids and tissues, coupled with its photoreactivity, makes it relevant to neonatal jaundice phototherapy.
- Bilirubin and riboflavin share nearly identical absorption maxima (445-450 nm).
Purpose of the Study:
- To investigate the impact of phototherapy on riboflavin levels in newborns.
- To understand the consequences of riboflavin photodegradation during neonatal jaundice treatment.
- To evaluate the necessity and safety of riboflavin supplementation in infants undergoing phototherapy.
Main Methods:
- Analysis of riboflavin's photoreactivity and absorption spectra.
- Assessment of erythrocyte glutathione reductase activity as an indicator of riboflavin status.
- Review of potential effects of phototherapy on bilirubin-albumin binding and DNA integrity.
- Consideration of riboflavin stores and absorption in premature infants.
Main Results:
- Blue light used in phototherapy causes riboflavin photodegradation, leading to diminished erythrocyte glutathione reductase and potential red cell lysis.
- Phototherapy can induce single- and double-strand breaks in intracellular DNA.
- Altered bilirubin-albumin binding may occur with co-administration of riboflavin and theophylline.
- Premature infants often have low initial riboflavin stores and reduced enteral absorption, exacerbating deficiency risk.
Conclusions:
- Neonatal phototherapy for jaundice poses a risk of riboflavin deficiency, particularly in premature infants with low stores and absorption.
- Supplementation may be beneficial but requires careful adjustment of dosage, timing, and administration to prevent adverse effects.
- Monitoring riboflavin status and considering supplementation are crucial for infants undergoing phototherapy.
Abstract:
The biologically most important flavins are riboflavin and its related nucleotides, all highly sensitive to light. It is because of its photoreactivity and its presence in almost all body fluids and tissues that riboflavin assumes importance in phototherapy of neonatal jaundice. The absorption maxima of both bilirubin and riboflavin in the body are nearly identical: 445-450 (447) nm. In consequence, blue visible light will cause photoisomerization of bilirubin accompanied by photodegradation of riboflavin. This results in diminished erythrocyte glutathione reductase, which indicates generalized tissue riboflavin deficiency and red cell lysis. Single- and double-strand breaks in intracellular DNA have occurred with phototherapy. This light exposure of neonates may result also in alterations of bilirubin-albumin binding in the presence of both riboflavin and theophylline (the latter frequently given to prevent neonatal apnea). Many newborns, especially if premature, have low stores of riboflavin at birth. The absorptive capacity of premature infants for enteral riboflavin is likewise reduced. Consequently, inherently low stores and low intake of riboflavin plus phototherapy for neonatal jaundice will cause a deficiency of riboflavin at a critical period for the newborn. Supplementation to those infants most likely to develop riboflavin deficiency is useful, but dosage, time, and mode of administration to infants undergoing phototherapy must be carefully adjusted to avoid unwanted side effects.